The invention discloses cancer vaccines comprising lipid-nucleic acid formulations in combination with one or more tumor-associated antigens which are capable of stimulating strong, Th-1 biased cellular immune responses to said tumor-associated antigens in vivo. It is further disclosed the subject cancer vaccines provide therapeutic efficacy in treating tumors in an animal.